Cargando…
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779686/ https://www.ncbi.nlm.nih.gov/pubmed/33408716 http://dx.doi.org/10.3389/fimmu.2020.601497 |
_version_ | 1783631383837540352 |
---|---|
author | Li, Wei Peng, Anghui Wu, Huajun Quan, Yingyao Li, Yong Lu, Ligong Cui, Min |
author_facet | Li, Wei Peng, Anghui Wu, Huajun Quan, Yingyao Li, Yong Lu, Ligong Cui, Min |
author_sort | Li, Wei |
collection | PubMed |
description | Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment. |
format | Online Article Text |
id | pubmed-7779686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77796862021-01-05 Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy Li, Wei Peng, Anghui Wu, Huajun Quan, Yingyao Li, Yong Lu, Ligong Cui, Min Front Immunol Immunology Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment. Frontiers Media S.A. 2020-12-21 /pmc/articles/PMC7779686/ /pubmed/33408716 http://dx.doi.org/10.3389/fimmu.2020.601497 Text en Copyright © 2020 Li, Peng, Wu, Quan, Li, Lu and Cui http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Wei Peng, Anghui Wu, Huajun Quan, Yingyao Li, Yong Lu, Ligong Cui, Min Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title | Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title_full | Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title_fullStr | Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title_full_unstemmed | Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title_short | Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy |
title_sort | anti-cancer nanomedicines: a revolution of tumor immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779686/ https://www.ncbi.nlm.nih.gov/pubmed/33408716 http://dx.doi.org/10.3389/fimmu.2020.601497 |
work_keys_str_mv | AT liwei anticancernanomedicinesarevolutionoftumorimmunotherapy AT penganghui anticancernanomedicinesarevolutionoftumorimmunotherapy AT wuhuajun anticancernanomedicinesarevolutionoftumorimmunotherapy AT quanyingyao anticancernanomedicinesarevolutionoftumorimmunotherapy AT liyong anticancernanomedicinesarevolutionoftumorimmunotherapy AT luligong anticancernanomedicinesarevolutionoftumorimmunotherapy AT cuimin anticancernanomedicinesarevolutionoftumorimmunotherapy |